<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">goslasmed</journal-id><journal-title-group><journal-title xml:lang="ru">Лазерная медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Laser Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8004</issn><issn pub-type="epub">2686-8644</issn><publisher><publisher-name>Skobelkin Centre for Laser Medicine - a branch of the Federal Clinical Center for High Medical Technologies, FMBA of Russia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37895/2071-8004-2020-24-2-3-85-89</article-id><article-id custom-type="elpub" pub-id-type="custom">goslasmed-530</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCHES</subject></subj-group></article-categories><title-group><article-title>Контроль боли и гиперурикемии у больных с тофусной подагрой после операции на суставах</article-title><trans-title-group xml:lang="en"><trans-title>Controlling pain and hyperuricemia in patients with tophaceous gout after joints surgery</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2538-2132</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Chen</surname><given-names>Jianchun</given-names></name><name name-style="western" xml:lang="en"><surname>Chen</surname><given-names>Jianchun</given-names></name></name-alternatives><bio xml:lang="ru"><p>Chen Jianchun – rheumatology department</p><p>121 West 2nd Ring Road, Funan Street, Qingyang District, Chengdu city, Sichuan Province</p></bio><bio xml:lang="en"><p>Chen Jianchun – rheumatology department</p><p>121 West 2nd Ring Road, Funan Street, Qingyang District, Chengdu city, Sichuan Province</p></bio><email xlink:type="simple">cjc18030541834@163.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5367-2885</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Zhong</surname><given-names>Xiaofeng</given-names></name><name name-style="western" xml:lang="en"><surname>Zhong</surname><given-names>Xiaofeng</given-names></name></name-alternatives><bio xml:lang="ru"><p>Zhong Xiaofeng – rheumatology department</p><p>121 West 2nd Ring Road, Funan Street, Qingyang District, Chengdu city, Sichuan Province</p></bio><bio xml:lang="en"><p>Zhong Xiaofeng – rheumatology department</p><p>121 West 2nd Ring Road, Funan Street, Qingyang District, Chengdu city, Sichuan Province</p></bio><email xlink:type="simple">280728202@qq.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1795-4073</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Guo</surname><given-names>Yichuan</given-names></name><name name-style="western" xml:lang="en"><surname>Guo</surname><given-names>Yichuan</given-names></name></name-alternatives><bio xml:lang="ru"><p>Guo Yichuan – rheumatology department</p><p>121 West 2nd Ring Road, Funan Street, Qingyang District, Chengdu city, Sichuan Province</p></bio><bio xml:lang="en"><p>Guo Yichuan – rheumatology department</p><p>121 West 2nd Ring Road, Funan Street, Qingyang District, Chengdu city, Sichuan Province</p></bio><email xlink:type="simple">2809936170@qq.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5133-9472</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Zheng</surname><given-names>Wuyan</given-names></name><name name-style="western" xml:lang="en"><surname>Zheng</surname><given-names>Wuyan</given-names></name></name-alternatives><bio xml:lang="ru"><p>Zheng Wuyan – head of academic research department</p><p>121 West 2nd Ring Road, Funan Street, Qingyang District, Chengdu city, Sichuan Province</p></bio><bio xml:lang="en"><p>Zheng Wuyan – head of academic research department</p><p>121 West 2nd Ring Road, Funan Street, Qingyang District, Chengdu city, Sichuan Province</p></bio><email xlink:type="simple">1642637460@qq.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8027-5693</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Oshmianska</surname><given-names>Nataliia</given-names></name><name name-style="western" xml:lang="en"><surname>Oshmianska</surname><given-names>Nataliia</given-names></name></name-alternatives><bio xml:lang="ru"><p>Oshmianska Nataliia – academic research department</p><p>121 West 2nd Ring Road, Funan Street, Qingyang District, Chengdu city, Sichuan Province</p></bio><bio xml:lang="en"><p>Oshmianska Nataliia – academic research department</p><p>121 West 2nd Ring Road, Funan Street, Qingyang District, Chengdu city, Sichuan Province</p></bio><email xlink:type="simple">1283182076@qq.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Chengdu Rheumatism Hospital<country>Китай</country></aff><aff xml:lang="en">Chengdu Rheumatism Hospital<country>China</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>29</day><month>01</month><year>2021</year></pub-date><volume>24</volume><issue>2-3</issue><fpage>85</fpage><lpage>89</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Chen J., Zhong X., Guo Y., Zheng W., Oshmianska N., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Chen J., Zhong X., Guo Y., Zheng W., Oshmianska N.</copyright-holder><copyright-holder xml:lang="en">Chen J., Zhong X., Guo Y., Zheng W., Oshmianska N.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://goslasmed.elpub.ru/jour/article/view/530">https://goslasmed.elpub.ru/jour/article/view/530</self-uri><abstract><p>Первичная задача при лечении тофузной (узелковой) подагры – это ее лечение медикаментозными средствами. К хирургическому вмешательству прибегают дополнительно, если нужно провести косметическую корректировку деформации в суставе или убрать его инвалидизирующую дисфункцию. Однако при этом вмешательстве возникают такие осложнения, как гиперурикемия и рецидив подагрического артрита, хорошо задокументированные в литературе. Цель: оценить эффективность низкоинтенсивной лазерной терапии (НИЛТ) на снижение уровня соли мочевой кислоты (уратов) у пациентов с тофусной подагрой, которые перенесли хирургическое вмешательство на суставах в ревматологической больнице Чэнду (Китай), и сравнить их с показателями пациентов, которые лечились только консервативно. Материалы и методы. Эффективность НИЛТ как уратснижающей терапии была исследована на 63 пациентах мужского пола с тофусной подагрой, которые лечились и были прооперированы в ревматологической больнице города Чэнду. Контрольную группу составили 63 пациента с подагрой, сопоставимых по возрасту и уровню мочевой кислоты до лечения, но которым проводили только консервативное лечение. Результаты. пациентам делали одноэтапную или двухэтапную операцию. Наиболее частым местом поражения были суставы стопы: пальцы ног (49,41%), голеностопный сустав (39,68%) и коленный сустав (34,92%), имевшие ограниченную подвижность. Уровни С-реактивного белка (СРБ) до лечения были повышены почти у всех пациентов (медиана 3,74 (0,2–48,75) мг/л) независимо от других сопутствующих заболеваний. Уратснижающая терапия заметно снизила уровень СРБ до 2,44 (0–33,27) мг/л в исследуемой группе и до 1,3 (0,13–31,72) мг/л в контрольной группе. После операции и уратснижающей терапии у всех пациентов отмечалось функциональное улучшение и уменьшение боли. Снижение уровня уратов в сыворотке было зарегистрировано у 96,83% пациентов основной группы и у 93,65% пациентов контрольной группы. Не было существенной разницы в уровне мочевой кислоты сыворотки у пациентов, перенесших операцию на суставах, и у пациентов, леченых только консервативно. Самый низкий средний уровень мочевой кислоты в сыворотке был у тех больных, которые дополнительно к хирургическому лечению получали лазеротерапию (280,93 ± 97,05 мкмоль/л), но из-за широкого диапазона вариаций разница с другими группами не была статистически значимой. Добавление лазеротерапии в комплексное лечение также помогло уменьшить боль почти вдвое (0,56 ± 0,56 против 1,04 ± 0,91), однако заметного противовоспалительного действия НилТ мы не зарегистрировали. Была установлена слабая прямая связь между уровнями мочевой кислоты и С-реактивного белка в сыворотке после лечения, но у пациентов, получавших лазерную терапию, СРБ повышался чаще, чем в контрольной группе. Заключение: Артроскопическая чистка сустава и другие хирургические методы лечения, как правило, никак не влияют на системную гиперурикемию и не могут рассматриваться как замена уратснижающей терапии. Однако наш опыт подтверждает, что своевременно проведенная операция способствует функциональному улучшению и уменьшению боли у больных подагрой. Низкоинтенсивная лазерная терапия не влияет на гиперурикемию и не гарантирует длительного системного противовоспалительного эффекта, но помогает дополнительно снять боль в суставах и таким образом улучшить лечебный эффект и качество жизни пациентов.</p></abstract><trans-abstract xml:lang="en"><p>The primary treatment of tophaceous gout is to control the disease by pharmacological therapy. Additional surgical intervention is used to correct cosmetic deformation in joints or disabling functional disorder; however, one of its reported complications is hyperuricemia and recurrent attacks of pain. Objectives: to access the effectiveness of Low Intensity Laser therapy as addition to urate lowering treatment in patients with tophaceous gout, who underwent joints surgery in the Chengdu Rheumatism Hospital, in comparison to those patients who received only nonsurgical treatment. Subjects and methods. The effectiveness of Low Intensity Laser therapy (LILT) and urate lowering treatment in patients with tophaceous gout was investigated in 63 male patients of Chengdu Rheumatism hospital with tophaceous gout who underwent joints surgery. Control group was formed of 63 gout patients comparable in age and pre-treatment uric acid, who received non-surgical treatment.Results. Patients underwent surgery in one or two sessions, the most common lesion site being foot joints: toes (49.41%), ankle (39.68%) and knee (34.92%), with restricted mobility in the mentioned joints. Levels of CRP before the treatment were elevated in almost all patients (median 3.74 (0.2, 48.75) mg/L), regardless of the other comorbidities. Urate lowering therapy notably reduced the levels of CRP to 2.44 (0, 33.27) mg/L in study group and to 1.3 (0.13, 31.72) mg/L in controls. After surgery and following urate lowering therapy all patients noted functional improvement and reduction of pain. Decrease in serum urate levels were reported in 96.83% of patients in study group and in 93.65% of controls. There was no significant difference in serum UA between patients who underwent joint surgery and who didn’t. Patients, who in addition to surgery received Low-Level Laser Therapy therapy, had a lowest mean serum UA after treatment (280.93 ± 97.05 μmol/L), but due to wide range of variation, difference to other groups wasn’t statistically significant. Addition of laser therapy also helped to reduce the pain almost twice (0.56±0.56 compared to 1.04 ± 0.91). However, we haven’t registered notable anti-inflammatory influence of LILT. There was a weak direct link established between levels of serum UA and CRP after treatment, but in patients receiving laser therapy, CRP was elevated more often, compared to those who weren’t prescribed with LILT or controls. Conclusion. Arthroscopic shaving and other surgical approaches focused on joints often doesn’t affect system hyperuricemia in any way and can’t be viewed as a substitute to urate lowering therapy. However, our experience confirms that timely performed surgery contribute to functional improvement and reduction of pain in gout patients. Low Intensity Laser therapy doesn’t affect hyperuricemia or guarantee long-term systemic anti-inflammatory effect, but help to additionally relieve pain in joints and thus enhance treatment effect and quality of patients’ life.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>подагра</kwd><kwd>гиперурикемия</kwd><kwd>низкоинтенсивная лазерная терапия (НИЛТ)</kwd><kwd>артроскопическая чистка сустава</kwd></kwd-group><kwd-group xml:lang="en"><kwd>gout</kwd><kwd>hyperuricemia</kwd><kwd>LILT</kwd><kwd>arthroscopic shaving</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Khanna P.P., Nuki G., Bardin T. et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health and Quality of Life Outcomes. 2012; 10 (1): 117. doi:10.1186/1477-7525-10-117.</mixed-citation><mixed-citation xml:lang="en">Khanna P.P., Nuki G., Bardin T. et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health and Quality of Life Outcomes. 2012; 10 (1): 117. doi:10.1186/1477-7525-10-117.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">McQueen F.M., Chhana A., Dalbeth N. Mechanisms of joint damage in gout: evidence from cellular and imaging studies. Nat. Rev. Rheumatol. 2012; 8 (3):173–81.</mixed-citation><mixed-citation xml:lang="en">McQueen F.M., Chhana A., Dalbeth N. Mechanisms of joint damage in gout: evidence from cellular and imaging studies. Nat. Rev. Rheumatol. 2012; 8 (3):173–81.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ragab G., Elshahaly M., Bardin T. Gout: An old disease in new perspective – A review. J. Adv. Res. 2017; 8: 495–511.</mixed-citation><mixed-citation xml:lang="en">Ragab G., Elshahaly M., Bardin T. Gout: An old disease in new perspective – A review. J. Adv. Res. 2017; 8: 495–511.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kasper I.R., Juriga M.D., Giurini J.M., Shmerling R.H. Treatment of Tophaceous Gout: When Medication is not Enough. Semin. Arthritis. Rheum. 2016; 45: 669–74.</mixed-citation><mixed-citation xml:lang="en">Kasper I.R., Juriga M.D., Giurini J.M., Shmerling R.H. Treatment of Tophaceous Gout: When Medication is not Enough. Semin. Arthritis. Rheum. 2016; 45: 669–74.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kumar S., Gow P. A survey of indications, results and complications of surgery for tophaceous gout. Journal of the New Zealand Medical Association. 2002; 115 (1158).</mixed-citation><mixed-citation xml:lang="en">Kumar S., Gow P. A survey of indications, results and complications of surgery for tophaceous gout. Journal of the New Zealand Medical Association. 2002; 115 (1158).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lee S.S., Sun I.F., Lu Y.M. et al. Surgical treatment of the chronic tophaceous deformity in upper extremities – the shaving technique. J. Plast. Reconstr. Aesthet. Surg. 2009; 62 (5): 669–74.</mixed-citation><mixed-citation xml:lang="en">Lee S.S., Sun I.F., Lu Y.M. et al. Surgical treatment of the chronic tophaceous deformity in upper extremities – the shaving technique. J. Plast. Reconstr. Aesthet. Surg. 2009; 62 (5): 669–74.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wang C.C., Lien S.B., Huang G.S. et al. Arthroscopic elimination of monosodium urate deposition of the first metatarsophalangeal joint reduces the recurrence of gout. Arthroscopy. 2009; 25 (2): 153–8.</mixed-citation><mixed-citation xml:lang="en">Wang C.C., Lien S.B., Huang G.S. et al. Arthroscopic elimination of monosodium urate deposition of the first metatarsophalangeal joint reduces the recurrence of gout. Arthroscopy. 2009; 25 (2): 153–8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Manpreet Singh, Kaushik Madan L. A Review on Treatments of Gout for Future Aspects. Research and Reviews: A Journal of Pharmaceutical Science. 2017; 8 (3): 1–6.</mixed-citation><mixed-citation xml:lang="en">Manpreet Singh, Kaushik Madan L. A Review on Treatments of Gout for Future Aspects. Research and Reviews: A Journal of Pharmaceutical Science. 2017; 8 (3): 1–6.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Khanna D., Fitzgerald J.D., Khanna P.P. et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64 (10):1431–46.</mixed-citation><mixed-citation xml:lang="en">Khanna D., Fitzgerald J.D., Khanna P.P. et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64 (10):1431–46.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Felizatti A.L., Bomfim F.R., Bovo J.L. et al. Effects of low-level laser therapy on the organization of articular cartilage in an experimental microcrystalline arthritis model. Lasers in Medical Science. 2019; 34 (7): 1401–1412. doi:10.1007/s10103-01902740-5.</mixed-citation><mixed-citation xml:lang="en">Felizatti A.L., Bomfim F.R., Bovo J.L. et al. Effects of low-level laser therapy on the organization of articular cartilage in an experimental microcrystalline arthritis model. Lasers in Medical Science. 2019; 34 (7): 1401–1412. doi:10.1007/s10103-01902740-5.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Castano A.P., Dai T., Yaroslavsky I. et al. Low-level laser therapy for zymosan-induced arthritis in rats: Importance of illumination time. Lasers in Surgery and Medicine. 2007; 39 (6): 543–550. doi:10.1002/lsm.20516.</mixed-citation><mixed-citation xml:lang="en">Castano A.P., Dai T., Yaroslavsky I. et al. Low-level laser therapy for zymosan-induced arthritis in rats: Importance of illumination time. Lasers in Surgery and Medicine. 2007; 39 (6): 543–550. doi:10.1002/lsm.20516.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Campana V.R., Moya M., Gavotto A. et al. Laser Therapy on Arthritis Induced by Urate Crystals. Photomedicine and Laser Surgery. 2004; 22 (6): 499–503. doi:10.1089/pho.2004.22.499.</mixed-citation><mixed-citation xml:lang="en">Campana V.R., Moya M., Gavotto A. et al. Laser Therapy on Arthritis Induced by Urate Crystals. Photomedicine and Laser Surgery. 2004; 22 (6): 499–503. doi:10.1089/pho.2004.22.499.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rodriguez-Silva B.A., Carrillo-Delgado C.M., HernandezGarcia J.C. et al. Photochemical decomposition of uric acid crystals by ultra-short laser pulses. Optical Interactions with Tissue and Cells XXXI. 2020. doi:10.1117/12.2546099.</mixed-citation><mixed-citation xml:lang="en">Rodriguez-Silva B.A., Carrillo-Delgado C.M., HernandezGarcia J.C. et al. Photochemical decomposition of uric acid crystals by ultra-short laser pulses. Optical Interactions with Tissue and Cells XXXI. 2020. doi:10.1117/12.2546099.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Yan D., Zhang Y. Personalized Medicine of Urate-Lowering Therapy for Gout. Recent Advances in Gout. 2020. doi:10.5772/intechopen.85030.</mixed-citation><mixed-citation xml:lang="en">Yan D., Zhang Y. Personalized Medicine of Urate-Lowering Therapy for Gout. Recent Advances in Gout. 2020. doi:10.5772/intechopen.85030.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
